Heart-Saving pill for chemo patients? major trial underway
NCT ID NCT05271162
Summary
This study is testing if a drug called empagliflozin can protect the heart from damage caused by powerful chemotherapy drugs (anthracyclines). It involves 220 cancer patients with healthy hearts who are scheduled for high-dose chemotherapy. Half will receive empagliflozin and half a placebo pill to see if the drug prevents weakening of the heart muscle.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOTOXICITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Transfusion Medicine
NOT_YET_RECRUITINGWarsaw, Poland
Contact Phone: •••-•••-••••
-
National Institute of Oncology
RECRUITINGWarsaw, Poland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.